MX2020008746A - Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado. - Google Patents

Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado.

Info

Publication number
MX2020008746A
MX2020008746A MX2020008746A MX2020008746A MX2020008746A MX 2020008746 A MX2020008746 A MX 2020008746A MX 2020008746 A MX2020008746 A MX 2020008746A MX 2020008746 A MX2020008746 A MX 2020008746A MX 2020008746 A MX2020008746 A MX 2020008746A
Authority
MX
Mexico
Prior art keywords
prophylaxis
treatment
liver cancer
derivatives
sup
Prior art date
Application number
MX2020008746A
Other languages
English (en)
Spanish (es)
Inventor
Hongying Yun
Carola Ries
Hong Shen
Sabine Hoves
Thomas Poeschinger
Carina Hage
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2020008746A publication Critical patent/MX2020008746A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2020008746A 2018-02-28 2019-02-26 Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado. MX2020008746A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018077501 2018-02-28
PCT/EP2019/054729 WO2019166432A1 (fr) 2018-02-28 2019-02-26 Nouveaux composés sulfonimidoylpurinone substitués en position 7 et dérivés pour le traitement et la prophylaxie du cancer du foie

Publications (1)

Publication Number Publication Date
MX2020008746A true MX2020008746A (es) 2020-09-28

Family

ID=65685310

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008746A MX2020008746A (es) 2018-02-28 2019-02-26 Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado.

Country Status (19)

Country Link
EP (1) EP3758707A1 (fr)
JP (1) JP7089596B2 (fr)
KR (1) KR20200128414A (fr)
CN (1) CN111801100B (fr)
AR (1) AR114419A1 (fr)
AU (1) AU2019228654A1 (fr)
BR (1) BR112020016509A2 (fr)
CA (1) CA3091950A1 (fr)
CL (1) CL2020002139A1 (fr)
CO (1) CO2020010306A2 (fr)
IL (1) IL276817A (fr)
MA (1) MA52412A (fr)
MX (1) MX2020008746A (fr)
PE (1) PE20211456A1 (fr)
PH (1) PH12020551343A1 (fr)
RU (1) RU2020131012A (fr)
SG (1) SG11202008291XA (fr)
TW (1) TW202003518A (fr)
WO (1) WO2019166432A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
EA202091696A1 (ru) 2018-02-28 2021-01-27 Новартис Аг ПРОИЗВОДНЫЕ 10-(ДИ(ФЕНИЛ)МЕТИЛ)-4-ГИДРОКСИ-8,9,9a,10-ТЕТРАГИДРО-7H-ПИРРОЛО[1',2':4,5]ПИРАЗИНО[1,2-b]ПИРИДАЗИН-3,5-ДИОНА И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ РЕПЛИКАЦИИ ОРТОМИКСОВИРУСА ДЛЯ ЛЕЧЕНИЯ ГРИППА
KR102409595B1 (ko) 2020-06-29 2022-06-17 한국과학기술연구원 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체
CN112420196A (zh) * 2020-11-20 2021-02-26 长沙市弘源心血管健康研究院 急性心肌梗死患者5年内生存率的预测方法和系统
CN119604517A (zh) * 2022-07-14 2025-03-11 豪夫迈·罗氏有限公司 用于治疗癌症的磷酰基嘌呤酮化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
AU2009333559B2 (en) 2008-12-09 2015-03-12 Gilead Sciences, Inc. Modulators of toll-like receptors
BRPI1010937A2 (pt) * 2009-05-21 2019-09-24 Astrazeneca Ab composto, uso de um composto, e, método para tratar câncer
MX2012004706A (es) * 2009-10-22 2012-06-08 Gilead Sciences Inc Derivados de purina o deazapurina utiles para el tratamiento de (inter alia) infecciones virales.
US20110150836A1 (en) * 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
WO2011163594A2 (fr) 2010-06-24 2011-12-29 Alkermes, Inc. Promédicaments de composés nh-acides : dérivés esters, carbonates, carbamates et phosphonates
RU2013110889A (ru) * 2010-08-13 2014-09-20 Бейлор Рисёч Инститьют Новые вакцинные адъюванты на основе адъювантов-антител, нацеливающих непосредственно на антигенпрезентирующие клетки
CN107580596B (zh) 2015-05-08 2020-07-14 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的磺亚氨酰基嘌呤酮化合物和衍生物
SG11201802769RA (en) 2015-10-29 2018-05-30 Novartis Ag Antibody conjugates comprising toll-like receptor agonist
PE20190476A1 (es) * 2016-08-29 2019-04-04 Hoffmann La Roche Compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica
CN109715214B (zh) * 2016-09-13 2022-03-04 豪夫迈·罗氏有限公司 Tlr7激动剂和hbv衣壳组装抑制剂的组合治疗

Also Published As

Publication number Publication date
CL2020002139A1 (es) 2021-01-04
TW202003518A (zh) 2020-01-16
AU2019228654A1 (en) 2020-09-03
JP7089596B2 (ja) 2022-06-22
MA52412A (fr) 2021-06-02
JP2021514972A (ja) 2021-06-17
EP3758707A1 (fr) 2021-01-06
RU2020131012A (ru) 2022-03-28
PE20211456A1 (es) 2021-08-05
BR112020016509A2 (pt) 2020-12-15
PH12020551343A1 (en) 2021-06-21
CO2020010306A2 (es) 2020-08-31
AR114419A1 (es) 2020-09-02
CN111801100B (zh) 2023-10-24
WO2019166432A1 (fr) 2019-09-06
CN111801100A (zh) 2020-10-20
SG11202008291XA (en) 2020-09-29
CA3091950A1 (fr) 2019-09-06
IL276817A (en) 2020-10-29
KR20200128414A (ko) 2020-11-12

Similar Documents

Publication Publication Date Title
MX2023010806A (es) 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas.
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
MX2021006902A (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica.
MX2020001235A (es) Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
EP4365179A3 (fr) Nouveaux dérivés de rapamycine
PH12017501061A1 (en) 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
EP4374858A3 (fr) Dérivés de la benzimidazolone en tant qu'inhibiteurs du récepteur bcl6
WO2015200481A8 (fr) Inhibiteurs de mnk et procédés associés
PH12020551343A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
MX379459B (es) Inhibidores de bromodominios.
TN2016000501A1 (en) Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MX2020010690A (es) Oxiesteroles y metodos de uso de los mismos.
EP4316591A3 (fr) Oxystérols et leurs procédés d'utilisation
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
CR20200584A (es) Compuestos tetrahidro-1h-pirazino [2,1-a] isoindolilquinolina para el tratamiento de enfermedades autoinmunes
MX378932B (es) Triazoles sustituidos y métodos relacionados a estos.
PH12021552513A1 (en) Pyrrole compounds
PH12021552953A1 (en) Tricyclic compounds
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
MX379704B (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
TN2016000459A1 (en) Cycloalkyl-linked diheterocycle derivatives.
CR20220231A (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria